




25. (NEW CLAIM)

A method of treating undesired angiogenesis in a human or animal comprising the step of administering to the human or animal with the undesired angiogenesis a composition comprising an effective amount of an angiogenesis-inhibiting compound selected from the group consisting of the following compounds:




wherein R1, R2, R3 and R4 can be selected from: -H; -OH; =O, straight chained and branched alkanes, alkenes, alkynes; cyclic alkanes, alkenes, and alkynes; combinations of cyclic and acyclic alkanes, alkenes, and alkynes; alcohol, aldehyde, ketone, carboxylic acid, ester, or ether moieties in combination with acyclic, cyclic, or combination acyclic/cyclic moieties; aza; amino; -XOn or -O-XOn, (where X=N and n=2; X=S and n=2 or 3; or X=P and n=1-3); and halogens; R5, R6, R7, and R8 are each independently selected from:




No R^x *Has an N* *Has an O* *or* *N=O*?

or -O- where Y is optional and is the same as defined above for R1; and R10 is the same as defined above for R1, or (where Y is absent) R10 is =O; and R9 is a moiety having formula A) or B):


A)



where each of R11 - R17 is independently the same as defined above for R5;




where R₁₈, R₁₉ and R₂₀ are, independently selected from




and n=1 to 4.

26. (NEW CLAIM) The method of Claim 25, wherein the compound is α - thalidomide having the following formula;




27. (NEW CLAIM) The method of Claim 25, wherein the compound is EM-138 having the following formula;



28. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-aminothalidomide having the following formula;



29. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxythalidomide, having the following formula;



30. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxy-EM-138, having the following formula;



31. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxy-EM-27, having the following formula;



32. (NEW CLAIM)

The method of Claim 25, wherein the compound is


3-hydroxyphthalimido-glutamic acid, having the following formula;



33. (NEW CLAIM)

The method of Claim 25, wherein the compound is

EM-12, having the following formula;



34. (NEW CLAIM)

The method of Claim 25, wherein the compound is

a thalidomide metabolite or hydrolysis product.

35. (NEW CLAIM)

The method of Claim 25, wherein the composition

further comprises an epoxide hydrolase inhibitor.

36. (NEW CLAIM)

The method of Claim 25, wherein the undesired

angiogenesis is associated with retinal neovascularization.

37. (NEW CLAIM)

The method of Claim 25, wherein the undesired

angiogenesis is associated with choroidal neovascularization.

38. (NEW CLAIM)

The method of Claim 25, wherein the undesired

angiogenesis is associated with diabetic retinopathy.